Recombinant Mouse Palmitoyltransferase ZDHHC5 (Zdhhc5)

What is the cellular localization pattern of ZDHHC5 in neuronal cells?

ZDHHC5 shows distinctive subcellular localization patterns that differ from other palmitoyl acyltransferases (PATs). In dorsal root ganglion (DRG) neurons, ZDHHC5 and its close homolog ZDHHC8 demonstrate significant axonal enrichment compared to other PATs. While most PATs are predominantly detected in neuronal cell bodies, ZDHHC5 is strongly detected in distal axonal fractions, with immunocytochemical studies confirming robust axonal signals .

In hippocampal neurons, ZDHHC5 localizes to the plasma membrane, with notable presence at intercalated discs, cell surface, and perinuclear regions . This distribution is functionally significant as ZDHHC5 remains at the synaptic membrane under basal conditions through FYN-mediated phosphorylation, which prevents association with endocytic proteins. Upon neuronal activity, ZDHHC5 undergoes internalization and trafficking from spines to dendritic shafts where it palmitoylates specific substrates like delta-catenin/CTNND2 .

How does ZDHHC5 enzymatic function differ from other DHHC-family proteins?

Unlike most ZDHHC family proteins that predominantly localize to the early biosynthetic pathway (endoplasmic reticulum and Golgi), ZDHHC5 is among the fewer enzymes that localize to the endosomal system . This unique localization allows ZDHHC5 to modify a distinct subset of substrates and influence their trafficking, turnover, and function differently than other PATs.

ZDHHC5 contains an amphipathic helix flanked by two cysteine residues (C236, C237) that can be palmitoylated, suggesting a self-regulatory mechanism . The enzyme's regulation is further complexified by its own palmitoylation status in its C-terminal tail, which mediates its response to β-adrenergic signaling and facilitates interactions with substrates like Na+/K+ ATPase .

A key distinguishing feature is ZDHHC5's dual mechanism of action: it directly palmitoylates target proteins and indirectly affects protein homeostasis by influencing the endocytic/recycling pathway, thereby impacting a broader range of cellular proteins than its direct substrates alone .

What are the validated methods for detecting ZDHHC5-mediated protein palmitoylation in experimental settings?

Several complementary methods have been validated for detecting ZDHHC5-mediated protein palmitoylation:

Acyl-PEG Exchange (APE) Assay
This method allows quantitative assessment of palmitoylation levels by replacing palmitoyl groups with PEG moieties, causing a detectable molecular weight shift during gel electrophoresis. This technique has been successfully used to evaluate FAK palmitoylation status in glioblastoma cell lines .

Metabolic Incorporation Assay
This approach involves metabolic labeling with palmitate analogs followed by click chemistry to visualize palmitoylated proteins. This method has proven valuable for identifying potential ZDHHC5 substrates and specific palmitoylation sites, as demonstrated in the identification of FAK Cys456 as a ZDHHC5 target site .

Acyl-Biotin Exchange (ABE)
This biochemical method exchanges palmitoyl groups for biotin labels, allowing purification and detection of palmitoylated proteins. This technique was successfully employed to demonstrate that ZDHHC5/8 knockdown reduces Gp130 palmitoylation .

Palmitoylation Site Mutation Analysis
Site-directed mutagenesis of predicted palmitoylation sites (cysteine residues) coupled with functional assays provides definitive evidence for the role of specific palmitoylation events in protein function and localization .

What strategies are effective for generating and validating ZDHHC5 knockout models?

Research has employed several effective strategies for generating ZDHHC5 knockout models:

CRISPR/Cas9 Genome Editing
This method has been successfully used to generate ZDHHC5 knockout cell lines by targeting specific exons. For example, RPE-1 ZDHHC5 knockout cells were created using guide RNA targeted against ZDHHC5, resulting in a homozygous 1-bp insertion in exon 5 leading to premature termination (c.549_550insG/p.Ala184GlyfsX35) . Similar approaches were used with guide RNAs provided by Horizon Discovery to generate ZDHHC5 knockout HEK cells .

shRNA-Mediated Knockdown
For studies where complete knockout might affect cell viability, shRNA-mediated knockdown provides a valuable alternative. This approach has been successfully used in neurons, where lentivirus expressing shRNA against ZDHHC5 effectively reduced protein expression as confirmed by Western blotting and immunocytochemistry .

Validation Strategies:

• Western blotting with specific antibodies (e.g., detecting an ~80 kDa band that disappears in knockdown/knockout cells)

• Genomic sequencing to confirm mutations in the ZDHHC5 gene

• Functional assays measuring palmitoylation of known ZDHHC5 substrates

• Rescue experiments by reintroducing wild-type or catalytically inactive (DHHS5) variants

Important Considerations:

• When validating knockouts, it's crucial to use antibodies targeting different epitopes or multiple detection methods

• Compensatory mechanisms involving other ZDHHC enzymes may emerge, necessitating careful interpretation of results

• Tissue/cell-specific effects may vary, requiring validation in the specific experimental system of interest

How does ZDHHC5-mediated palmitoylation contribute to cancer progression mechanisms, particularly in glioblastoma?

ZDHHC5 plays multifaceted roles in cancer progression, particularly in glioblastoma (GBM), through several key mechanisms:

FAK Palmitoylation and Activation
ZDHHC5 catalyzes S-palmitoylation of focal adhesion kinase (FAK) at Cys456, which is crucial for FAK membrane localization and activation. Knockdown of ZDHHC5 abrogates FAK S-palmitoylation and membrane distribution, thereby impairing cell proliferation, invasion, and epithelial-mesenchymal transition (EMT) in GBM cells. This suggests that ZDHHC5-mediated FAK palmitoylation is a critical mechanism promoting GBM development .

p53-Mutant Glioma Mechanisms
In p53-mutant gliomas (representing approximately 30% of cases with poor prognosis), ZDHHC5 is overexpressed compared to normal brain tissue. Mechanistic investigations revealed that mutant p53 transcriptionally upregulates ZDHHC5 alongside nuclear transcription factor NF-Y. This overexpression contributes to glioma development by altering the palmitoylation and phosphorylation status of the tumor suppressor EZH2, thereby promoting the self-renewal capacity and tumorigenicity of glioma stem-like cells .

Experimental Evidence in Animal Models
In xenograft experiments using nude mice, stable ZDHHC5-knockdown tumors (Mia PaCa-2 cells) showed significantly smaller tumor weight/volume compared to control tumors. Immunohistochemical analysis revealed lower expression of Ki67 (a proliferation marker) in the ZDHHC5-knockdown group. Molecular analysis indicated that ZDHHC5 palmitoylates membrane proteins that subsequently influence phosphorylation of downstream signaling proteins like Akt, c-Raf, MEK, and ERK .

These findings collectively establish ZDHHC5 as a potential therapeutic target for cancer treatment, particularly for aggressive tumors like GBM and those harboring p53 mutations.

What is the role of ZDHHC5 in cardiac pathophysiology and how does its expression change during heart disease progression?

ZDHHC5 demonstrates complex temporal and context-dependent expression patterns during cardiac disease progression:

In Left Ventricular Hypertrophy (LVH)
Studies in mouse models of pressure overload-induced LVH show that ZDHHC5 expression is significantly increased from the earliest timepoint (3 days post-banding) and remains elevated at 2-weeks and 8-weeks after surgery. This suggests ZDHHC5 upregulation is an early event in the pathogenesis of cardiac hypertrophy .

In Heart Failure (HF)
Intriguingly, ZDHHC5 expression patterns differ in heart failure compared to hypertrophy. In rabbit and pig models of ischemic heart failure, ZDHHC5 expression was either unchanged (rabbit) or modestly reduced (pig). In human ischemic heart failure samples, ZDHHC5 expression was significantly reduced compared to organ donor controls .

Palmitoylation Changes Despite Expression Changes
Surprisingly, changes in ZDHHC5 expression correlate poorly with palmitoylation of its substrates. For example, despite ZDHHC5 overexpression in LVH models, palmitoylation of phospholemman (PLM) remained unchanged while sodium-calcium exchanger 1 (NCX1) palmitoylation was significantly reduced. Similarly, in heart failure models, NCX1 palmitoylation was significantly reduced in animal models but increased in human samples .

Self-Regulation Through ZDHHC5 Palmitoylation
ZDHHC5 itself undergoes palmitoylation in its C-terminal tail, which mediates its response to β-adrenergic signaling and facilitates interaction with substrates. In heart failure, ZDHHC5 palmitoylation changes in a similar pattern to NCX1 palmitoylation - significantly reduced in pig models but modestly increased in human samples .

These findings suggest that ZDHHC5's role in cardiac pathophysiology extends beyond simple expression level changes and likely involves complex regulatory mechanisms including its own post-translational modifications and acyl-CoA substrate availability.

What determines ZDHHC5 substrate specificity and how can researchers identify novel substrates?

ZDHHC5 substrate specificity is determined by multiple factors operating in concert:

Structural Determinants
The presence of an amphipathic helix flanked by cysteine residues (C236, C237) in ZDHHC5's structure appears critical for binding certain substrates, such as the Na+/K+ pump. The proximity of these modifiable residues to substrate binding sites suggests that ZDHHC5's own palmitoylation status may regulate substrate recruitment .

Direct vs. Indirect Interactions
Substrate specificity can involve direct protein-protein interactions or may be mediated through adapter proteins. For example, experiments with biotinylated peptides covering the PLM intracellular C-tail showed that ZDHHC5 does not interact directly with PLM, suggesting interaction through another subunit like the Na+/K+ pump α subunit .

Subcellular Localization
ZDHHC5's unique localization to the endosomal system (unlike most PATs that localize to ER/Golgi) allows it to encounter and modify a distinct subset of substrates. Studies using PC biosensors designed to localize to specific cellular sites showed that ZDHHC5 affects proteolytic activity in distinct subcellular compartments, including late endosomes, GPI-rich domains, and potentially the plasma membrane .

Methods for Novel Substrate Identification:

• Comparative Palmitoylomics
  Compare palmitoylated proteomes in control versus ZDHHC5-knockdown/knockout cells using Acyl-Biotin Exchange coupled with mass spectrometry.

• Proximity Labeling
  Use BioID or APEX2 fused to ZDHHC5 to identify proteins in close proximity, potentially representing substrates or regulatory partners.

• Co-Immunoprecipitation Coupled with Palmitoylation Assays
  Immunoprecipitate ZDHHC5 and identify co-precipitating proteins that also show changes in palmitoylation status upon ZDHHC5 manipulation .

• Candidate Approach Based on Consensus Sequences
  While no strong consensus sequence exists for palmitoylation sites, analyzing cysteine residues in juxtamembrane regions of transmembrane proteins or within hydrophobic pockets of soluble proteins can identify candidate substrates.

How do post-translational modifications of ZDHHC5 itself regulate its enzymatic activity and substrate specificity?

ZDHHC5 undergoes multiple post-translational modifications that intricately regulate its function:

Self-Palmitoylation
ZDHHC5 undergoes palmitoylation at its active site cysteine during autopalmitoylation before transferring palmitate to substrate cysteines. Additionally, ZDHHC5 is palmitoylated at sites in its C-terminal tail, which critically affects its function. In heart failure models, ZDHHC5 palmitoylation changes mirror those seen in its substrate NCX1, suggesting coordinated regulation .

Phosphorylation
Phosphorylation plays a dual role in ZDHHC5 regulation:

• FYN-mediated phosphorylation keeps ZDHHC5 at the synaptic membrane under basal conditions by preventing association with endocytic proteins .

• Conversely, other phosphorylation events have been observed to inactivate ZDHHC5, suggesting context-dependent effects .

O-GlcNAcylation
O-GlcNAcylation of ZDHHC5 enhances its association with phospholemman (PLM) and increases PLM palmitoylation, representing another layer of regulation that may be particularly relevant in cardiac contexts .

Regulatory Mechanisms:

• Substrate Availability Regulation
  ZDHHC5 activity may be controlled by the availability of its acyl-CoA substrate, synthesized by acyl-CoA synthetases (ACSLs). This provides a potential metabolic regulatory mechanism linking cellular energetics to palmitoylation .

• Membrane Localization Control
  ZDHHC5's C-terminal tail contains a binding site for the Na+/K+ ATPase and the ZDHHC5 accessory protein GOLGA7, which controls its membrane localization. Changes in ZDHHC5 palmitoylation can alter these interactions and thereby affect its substrate accessibility .

• Activity-Dependent Trafficking
  In neurons, neuronal activity enhances the internalization and trafficking of ZDHHC5 from spines to dendritic shafts where it palmitoylates substrates like delta-catenin/CTNND2. This represents a dynamic regulatory mechanism linking cellular activity to substrate targeting .

These multilayered regulatory mechanisms illustrate why ZDHHC5 function cannot be predicted by expression levels alone and underscore the importance of considering post-translational modifications when studying ZDHHC5 in any biological context.

What are the optimal experimental conditions for expressing and purifying recombinant mouse ZDHHC5 protein for in vitro studies?

Expression System Selection:

For functional recombinant mouse ZDHHC5 expression, mammalian expression systems are generally preferred over bacterial systems due to the protein's complex topology (multiple transmembrane domains) and post-translational modifications. HEK293 cells have been successfully used for ZDHHC5 expression, as documented in multiple studies .

Expression Construct Design:

• Epitope Tags: Include N- or C-terminal tags for detection and purification (HA-tag has been successfully used for ZDHHC5 )

• Transmembrane Domain Considerations: For full-length protein expression, optimize codon usage for mammalian expression and include appropriate signal sequences

• Catalytic Mutants: Generate a catalytically inactive control by mutating the critical DHHC motif to DHHS (zDHHS5)

• Truncation Variants: For specific domain studies, express the cytosolic domains separately

Purification Strategy:

For membrane proteins like ZDHHC5, a stepwise purification protocol is recommended:

• Cell lysis in buffer containing 1% digitonin or 1% Triton X-100 with protease inhibitors

• Initial purification using affinity chromatography (e.g., anti-HA affinity matrix)

• For higher purity, follow with size exclusion chromatography

• Maintain detergent concentration above critical micelle concentration throughout to prevent protein aggregation

Critical Quality Control Assessments:

• Western blotting to confirm expression of full-length protein (~78 kDa)

• Enzymatic activity assay using known substrates and Acyl-PEG Exchange or metabolic labeling methods

• Circular dichroism to confirm proper folding

• Dynamic light scattering to assess homogeneity and absence of aggregation

Storage Considerations:
Store purified ZDHHC5 in buffer containing glycerol (20-50%) and reducing agent at -80°C in small aliquots to avoid freeze-thaw cycles, which can reduce activity.

How can researchers effectively analyze the impact of ZDHHC5 on cellular palmitoylation networks rather than just individual substrates?

Analyzing ZDHHC5's impact on cellular palmitoylation networks requires integrative approaches:

Global Palmitoylome Analysis:

• Comparative Mass Spectrometry-Based Palmitoylomics
  Compare palmitoylated proteomes in wild-type versus ZDHHC5-deficient cells using ABE or metabolic labeling coupled with mass spectrometry. This approach revealed that palmitoylated proteins were significantly less abundant in ΔZDHHC5 cells, suggesting reduced half-life .

• Surface Proteome Analysis
  Perform surface biotinylation followed by streptavidin pull-down and mass spectrometry to analyze how ZDHHC5 affects the cell surface proteome. Studies have shown that ZDHHC5 depletion affects cell surface proteins independently of their direct palmitoylation, suggesting indirect effects on the endocytic pathway .

• Temporal Analysis Following Stimulation
  Monitor dynamic changes in the palmitoylome following cellular stimulation (e.g., receptor activation) in the presence or absence of ZDHHC5 to understand its role in activity-dependent palmitoylation.

Network Biology Approaches:

• Pathway Enrichment Analysis
  Identify biological pathways overrepresented among proteins affected by ZDHHC5 depletion. This can reveal cellular processes particularly dependent on ZDHHC5-mediated palmitoylation.

• Protein-Protein Interaction Networks
  Map interactions between ZDHHC5 and its substrates, as well as interactions among the substrates themselves, to identify functional modules regulated by ZDHHC5.

• Integrative Multi-Omics
  Combine palmitoylome data with transcriptomics, proteomics, and phosphoproteomics to understand how ZDHHC5-mediated palmitoylation intersects with other regulatory mechanisms.

Functional Validation Approaches:

• Biosensor Arrays
  Develop arrays of biosensors targeting different subcellular compartments to measure compartment-specific ZDHHC5 activity, as demonstrated with PC biosensors that revealed ZDHHC5's impact on late endosomes and GPI-rich domains .

• Systematic Mutagenesis of Palmitoylation Sites
  Perform systematic mutagenesis of palmitoylation sites in multiple ZDHHC5 substrates to assess the functional hierarchy and redundancy within the palmitoylation network.

• Functional Clustering
  Group ZDHHC5 substrates based on functional consequences of palmitoylation loss (e.g., mislocalization, degradation, activity changes) to identify common regulatory principles.

These approaches move beyond studying individual substrates to understand how ZDHHC5 orchestrates complex cellular processes through coordinated regulation of multiple targets within specific subcellular domains and signaling pathways.

How do researchers reconcile contradictory findings regarding ZDHHC5 expression and substrate palmitoylation in different disease models?

Several notable contradictions exist in ZDHHC5 research that require careful interpretation:

Expression-Function Discordance
A consistent observation across studies is that ZDHHC5 expression levels correlate poorly with palmitoylation of its substrates. For example, in cardiac hypertrophy models, increased ZDHHC5 expression was associated with unchanged PLM palmitoylation and decreased NCX1 palmitoylation, contrary to expectations . Similarly, overexpression of recombinant HA-ZDHHC5 in cardiomyocytes did not significantly change palmitoylation of NCX1 or PLM .

Species-Specific Differences
Significant differences exist between animal models and human samples. In heart failure studies, ZDHHC5 and NCX1 palmitoylation were significantly reduced in pig models but increased in human heart failure samples . These contradictions may reflect genuine species differences or variations in disease stage, severity, or etiology.

Reconciliation Approaches:

• Multi-level Regulation Model
  Researchers propose that ZDHHC5 function is regulated at multiple levels beyond expression, including:

  • ZDHHC5's own palmitoylation status

  • Phosphorylation and other post-translational modifications

  • Acyl-CoA substrate availability

  • Subcellular localization changes

  • Compensatory mechanisms involving other ZDHHC enzymes

• Context-Dependent Substrate Specificity
  Evidence suggests that ZDHHC5 substrate specificity may change depending on cellular context, explaining why altered expression doesn't uniformly affect all substrates. For example, ZDHHC5/8 knockdown only partially reduces Gp130 palmitoylation, suggesting other PATs may palmitoylate Gp130 in different cellular locations .

• Site-Specific Palmitoylation Effects
  Detection methods like ABE don't distinguish between different palmitoylation sites on multi-site substrates. ZDHHC5 may palmitoylate specific sites that are particularly important for function, while other sites might be modified by different enzymes .

• Disease Stage Considerations
  Contradictions may reflect different stages of disease progression. For example, ZDHHC5 upregulation may be an early compensatory response in cardiac hypertrophy, while downregulation in heart failure might represent maladaptive changes or exhaustion of compensatory mechanisms .

What are the current limitations in ZDHHC5 research methodology and how might they be addressed in future studies?

Current ZDHHC5 research faces several methodological limitations that future studies should address:

Technical Limitations:

• Palmitoylation Site Specificity
  Current methods like ABE and metabolic labeling can identify palmitoylated proteins but often cannot distinguish which specific cysteine residues are modified in multi-cysteine proteins. This is particularly problematic when studying proteins with multiple potential palmitoylation sites.

  Future Approach: Develop site-specific proteomic methods combining targeted mass spectrometry with palmitoyl-cysteine enrichment strategies.

• Temporal Resolution
  Most studies provide static snapshots of palmitoylation status rather than dynamic views of palmitoylation/depalmitoylation cycles.

  Future Approach: Develop real-time biosensors for palmitoylation to monitor dynamic changes in living cells, similar to approaches used for other post-translational modifications.

• In Vitro Reconstitution
  Membrane protein purification and reconstitution remain challenging, limiting in vitro biochemical studies of ZDHHC5 enzymatic activity and specificity.

  Future Approach: Develop improved membrane mimetics and reconstitution systems specifically optimized for palmitoyl transferases.

Biological System Limitations:

• Compensatory Mechanisms
  Genetic knockout or knockdown approaches may trigger compensatory upregulation of other ZDHHC enzymes, confounding interpretation.

  Future Approach: Use acute inhibition strategies like degrader technologies or small molecule inhibitors to minimize compensation; compare acute versus chronic inhibition effects.

• Cell-Type Specificity
  Most studies focus on a limited range of cell types, potentially missing tissue-specific functions and regulations.

  Future Approach: Systematic comparisons across diverse cell types; single-cell palmitoylomics to identify cell-specific ZDHHC5 functions.

• Indirect Effects
  Distinguishing direct ZDHHC5 substrates from proteins indirectly affected by altered endocytic trafficking remains challenging.

  Future Approach: Develop enzyme-substrate proximity labeling techniques specific to palmitoylation events; use rapid inducible systems to distinguish immediate from secondary effects.

Translational Research Gaps:

• Human Disease Relevance
  Discrepancies between animal models and human samples remain poorly understood.

  Future Approach: Develop improved human cellular models using patient-derived iPSCs; integrate clinical data with molecular studies to account for disease heterogeneity.

• Therapeutic Targeting
  Despite identification of ZDHHC5 as a potential therapeutic target in cancer, specific ZDHHC5 inhibitors with sufficient selectivity remain underdeveloped.

  Future Approach: Structure-based drug design focused on unique features of ZDHHC5; develop substrate-selective inhibition strategies rather than catalytic site inhibitors.

• Physiological Integration
  The integration of ZDHHC5 function with broader physiological processes and environmental factors remains underdeveloped.

  Future Approach: Systems biology approaches integrating metabolomics, palmitoylomics, and functional studies across different physiological and stress conditions.